When was BioCryst founded and when did the company go public? BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994. The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.
Similarly How many shares does BioCryst have? BioCryst Pharmaceuticals, Inc. (US:BCRX) has 429 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 134,860,198 shares. Largest shareholders include BlackRock Inc., Baker Bros.
Is BCRX a buy? Out of 6 analysts, 2 (33.33%) are recommending BCRX as a Strong Buy, 2 (33.33%) are recommending BCRX as a Buy, 2 (33.33%) are recommending BCRX as a Hold, 0 (0%) are recommending BCRX as a Sell, and 0 (0%) are recommending BCRX as a Strong Sell. What is BCRX’s earnings growth forecast for 2022-2024?
Additionally, Is BioCryst Pharmaceuticals a buy?
BioCryst Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.
What is the target price for BCRX stock?
Stock Price Targets
| High | $30.00 |
|---|---|
| Median | $17.50 |
| Low | $14.00 |
| Average | $19.50 |
| Current Price | $12.59 |
il y a 4 jours
Is BCRX overvalued? Slightly overvalued with limited growth.
Will BCRX go up? The 12 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 17.50, with a high estimate of 30.00 and a low estimate of 14.00. The median estimate represents a +53.64% increase from the last price of 11.39.
Why is BioCryst going up? The big gain came after the company provided an upbeat update on Monday. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. This figure brings the full-year 2021 sales for the drug to $122 million.
Is BioCryst a good company?
BioCryst Pharmaceuticals has an overall rating of 3.9 out of 5, based on over 10 reviews left anonymously by employees. 65% of employees would recommend working at BioCryst Pharmaceuticals to a friend and 62% have a positive outlook for the business.
Is Bcrx undervalued? BioCryst climbs after being named ‘the most undervalued stock in the market’ The influential retail investor crowd has a new favorite: BioCryst Pharmaceuticals (NASDAQ:BCRX). The stock has rallied ~22.3% in the premarket after a post in r/wallstreetbets called it ‘the most undervalued stock in the market.
How many employees does BioCryst have?
BioCryst Pharmaceuticals
| Type | Public |
|---|---|
| Key people | Jon P. Stonehouse , President and Chief Executive Officer |
| Products | RABIVAP |
| Revenue | $49 Million(2019) |
| Number of employees | 110 |
